// App-Quantinova.ai

3413 : Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221

Researchers

Presenter

  • Gary R. Zirpoli

Principal Investigators

  • Lara E. Sucheston-Campbell

  • Dawn L. Hershman

  • Gregory Ciupak

  • Warren Davis

  • Joseph M. Unger

  • Halle C.F. Moore

  • James A. Stewart

  • Claudine Isaacs

  • Timothy J. Hobday

  • Muhammad Salim

  • Robert B. Livingston

  • Gabriel N. Hortobagyi

  • Julie R. Gralow

  • Daniel F. Hayes

  • G. Thomas Budd

  • Kathy S. Albain

  • Christine B. Ambrosone

Medical Centers

  • Roswell Park Cancer Institute, Buffalo, NY

  • Columbia University, New York, NY

  • SWOG Statistical Center, Seattle, WA

  • Cleveland Clinic, Cleveland, OH

  • Baystate Medical Center, Springfield, MA

  • Lombardi Comprehensive Cancer Center, Washington, DC

  • Mayo Clinic, Rochester, MN

  • Allan Blair Cancer Centre, Regina, Saskatchewan, Canada

  • Arizona Cancer Center, Tucson, AZ

  • 1.MD Anderson Cancer Center, Houston, TX

  • Seattle Cancer Care Alliance, Seattle, WA

  • University of Michigan, Ann Arbor, MI

  • Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL.

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral neuropathy

  • Breast cancer

  • Solid malignancies

Biomarkers

  • TIMP Metallopeptidase Inhibitor 1

  • TNF Alpha Induced Protein 1

Drug/Treatment

  • Icosapent ethyl

  • Glucosamine

  • FA-8

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00070564

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved